Literature DB >> 27148941

Concomitant Presentation of Hemophagocytic Lymphohistiocytosis and Posttransplant Lymphoproliferative Disease-Like Lymphoma in a Mildly Immunosuppressed Leukemia Patient: An Unusual Association.

Mohamad G Sinno1, David Rosen1, Robert Wittler1.   

Abstract

We describe a 4-year-old female with pre-B-cell acute lymphoblastic leukemia on maintenance chemotherapy, who developed hemophagocytic lymphohistiocytosis (HLH) secondary to Epstein-Barr virus (EBV) infection, complicated by an aggressive lymphoproliferative disorder. Although there was no history of bone marrow transplant or underlying immunodeficiency, EBV triggered a post-transplant lymphoproliferative disease (PTLD)-like lymphoma. Multiple regimens of chemotherapy failed to induce remission and patient developed multiorgan failure. The association of HLH with EBV-related PTLD-like lymphoproliferative disorder is rare. We present this case to highlight this unusual association so that this highly fatal disease can be recognized and promptly addressed.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Epstein-Barr virus; HLH; acute leukemias; infections in immunocompromised hosts; lymphoproliferative disease

Mesh:

Substances:

Year:  2016        PMID: 27148941     DOI: 10.1002/pbc.26033

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Hemophagocytic Lymphohistiocytosis in Adults with Intraocular Involvement: Clinicopathologic Features of 3 Cases.

Authors:  M Adelita Vizcaino; Charles G Eberhart; Fausto J Rodriguez
Journal:  Ocul Oncol Pathol       Date:  2017-06-01

2.  Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years.

Authors:  Volker Strenger; Gerald Merth; Herwig Lackner; Stephan W Aberle; Harald H Kessler; Markus G Seidel; Wolfgang Schwinger; Daniela Sperl; Petra Sovinz; Anna Karastaneva; Martin Benesch; Christian Urban
Journal:  Ann Hematol       Date:  2018-02-06       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.